Starting in the mid 2000s and with scientific discoveries made in Paris, our insights into the role of the microbiome have grown substantially. Following clinical proof-of-concept demonstration with fecal transplants, initial efforts focused on simply adding bacteria strains to re-balance the microbiome. More recently, the field has moved on and our understanding of the function of the microbiome has advanced dramatically.
We develop bacterial consortia that address particular diseases, based on our profound insights into the functional networks of bacteria and how these are affected by a specific illness. We are passionate about technology and have adapted it to the point where we can rapidly create and co-cultured bacterial mixes. Results in several pre-clinical models for inflammatory and cancerous diseases are highly promising and encourage us to advance towards the clinic rapidly.